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control group of 6 patients with CAD having 2 sequential EMVM performed without any
intervention was compared in a similar fashion. Data were compared utilizing a paired T-
test.
Results: Unipolar voltage values in the injected area at baseline and at 4 months (10.2
mV and 9.9 mV) were similar (p=0.32). There was a significant difference (p=0.004)
when comparing unipolar voltage values in the peri-injection area at baseline and follow-
up (8.12mV and 9.8mv).There was no significant change in the control group(p>0.05).
Conclusion: Our results demonstrate that 1) unipolar voltage values were reproducible by
EMVM in the control group; 2) there were similar values of voltage in ABMMC injected
sites (all sites were initially viable); 3) there was a significant increase in voltage in the
area surrounding the injection sites. These findings may represent an expansion in myo-
cardial viability as reflected by an increase in unipolar voltage detected by EMVM and
may have important therapeutic implications.
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814-2 Time Course of Improvement Following Stem Cell 
Injections in Humans With Heart Failure
Emerson C. Perin, Hans F. Dohmann, Radovan Borejevic, Suzana A. Silva, Andre L. 
Sousa, Guilherme V. Silva, Joao A. Assad, Luciano Belem, Antonio C. Carvalho, Roberto 
Esporcatte, William K. Vaughn, Hans J. Dohmann, James T. Willerson, Texas Heart 
Institute, Houston, TX, Pro-Cardiaco Hospital, Rio de Janeiro, Brazil
Introduction: Preliminary evidence of perfusion and functional improvement following
Autologous Bone Marrow Mononuclear Cells (ABMMNC) transplantation into areas of
hibernating myocardium in end-stage ischemic heart disease patients has been
reported. There is no data regarding the time course of improvement. We evaluated func-
tional and clinical parameters in pts receiving ABMMNC up to 10 weeks.
Methods: In 14 pts with CAD and HF ABMMNC were injected into areas of hibernating
myocardium utilizing electromechanical mapping (MyoStar, Cordis, USA). Baseline and
weekly assessments of NYHA, CCSA and EF by 2Dechocardiogram (Simpson) were
performed. SPECT-MIBI was performed at baseline and 8 wks after ABMMNC transplan-
tation. ANOVA was utilized for comparisons between baseline and 8 wks and a general-
ized linear model with time strata for evaluation of peak improvement over time in regard
to functional class and ejection fraction.
Results: Pts had a significant reduction in total reversibility defect (from 15.15%±14.99%
to 4.53%±10.61%, p=0.022) at 8 wks. The NYHA class and CCSA improved from base-
line to 8 wks (2.21±0.89 to 1.14±0.36 , p=0.0003 and 2.64±0.84 to 1.28±0.61, p=0.0001
;respectively). The EF improved from 30±5% at baseline to 35±7% at 8 wks (p=0.02).
The significant improvement in NYHA ocurred at the 4 th wk time point (p=0.0002) and for
CCSA at the 7th wk time point (p=0.000006). A significant improvement in EF was also
observed between the 6th and 8th wks (p=0.04).
Conclusion: These preliminary data suggest that symptomatic, functional and myocardial
perfusion improvements with ABMMNC transplantation occur during the second month of
follow-up. This may help to contribute to the understanding of mechanisms of improve-
ment involved in ABMMNC transplantation.
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814-3 Autotransplantation of Bone Marrow Into Scarred 
Myocardium for the Improvement of Cardiac Function in 
Humans: Is It Durable and Safe?
Manuel Galiñanes, Derek Chin, Joan Davies, Mahmoud Loubani, Lizelle Bernhardt, 
Bashir Matata, The University of Leicester, Leicester, United Kingdom
Background: We have previously shown that autotransplantation of bone marrow into
scarred heart tissue in man is safe and improves cardiac function in the short term (first
10 months after surgery). To investigate the durability and safety of this procedure, 14
patients with previous myocardial infarctions who received unmanipulated bone marrow
injections into infarcted areas (250µl injections of bone marrow diluted in autologous
serum at a ratio of 1:2 and injected 1cm apart into the mid-depth of the left ventricular inf-
arct zone) at a time of elective bypass graft surgery, were followed-up 2 years after the
operation.
Methods: Digital Dobutamine stress echocardiography was used to assess the systolic
function of the left ventricle (global), coronary regions (regional) and infarct zones (seg-
mental). Off-line analysis with 2-4 loop side-by-side comparisons, to a resolution of 16
segments and 4 wall motion grades, was required to minimise spatial, interstage and
interstudy error. The wall motion score index (WMSI) was calculated by dividing the sum
of all grades by the number of segments scored.
Results: There were no deaths or clinically relevant arrhythmias during the 2 year follow-
up. The improvement in angina class (from 3.0±0.2 to 0.4±0.2; P<0.05) and dyspnoea
status (from 2.1±0.2 to 1.2±0.1; P<0.05) at 10 months after the operation was maintained
after 2 years (0.3±0.2 and 1.3±0.2, respectively; P<0.05 vs prior to surgery). None of the
patients were re-operated or had angioplasty but 1 patient was re-admitted to hospital
twice because of chest pain and another had a minor cerebrovascular accident. Echocar-
diography demonstrated that the peak dose improvement in segmental WMSI of areas
which received both bone marrow injections and revascularisation, previously observed
at 10 months (from 3.20±0.15 to 2.20±0.29; P<0.05), was maintained after 2 years
(2.40±0.44; P<0.05 vs pre-surgery). Segmental WMSI of areas that were grafted alone,
or injected alone, showed no improvement at any stage of the follow-up.
Conclusions: Autotransplantation of bone marrow is free of cardiac complications and the
early stress induced improvement in cardiac function is durable up to a period of at least
2 years.
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814-4 Mobilization of Bone Marrow Cells (Stem Cells) by 
Granulocyte-Colony Stimulating Factor Associated or 
Not With Intracoronary Stem Infusion Improves 
Exercise Capacity and Quality of Life in Severe Heart 
Failure
Edimar A. Bocchi, Fernando Bacal, University of São Paulo Medical School, São Paulo, 
Brazil, Fundação ProSangue Hemocentro, São Paulo, Brazil
Background: myocardium regeneration is emerging as a new option in the treatment of
congestive heart failure (CHF). Bone marrow stromall cells(BMC) are pluripotent and
when implanted into myocardial can undergo myocardial differentiation.We hypothesized
that the BMC mobilization to peripheral circulation by granulocyte-colony stimulating fac-
tor (GCS-F) associated or not with intracoronary BMC infusion could improve patients
(pts) with severe CHF.Methods: We prospectively studied 9 pts, mean age 50±18
years,with refractory CHF, under maximal tolerated optimized treatment with indication of
heart transplantation. We compared the BMC mobilization in CHF with a control group of
pts with orthopedic disease.CHF pts were divided in two groups: (1) 3 pts with suitable
peripheral venous access for apheresis procedure who underwent BMC mobilization,
collection of mononuclear cells (MNC) followed by MNC intracoronary infusion; and (2) 6
pts without venous access who underwent only BMC mobilization. BMC are mobilized by
600 mg GCS-F per day during at least 5 days until peripheral blood CD 34+ cells levels
achieve > 6/mm3 by flow cytometric analysis, monthly during 4 months. Results: The
peak CD34+ cells per mm3 was lower in CHF pts versus non-CHF pts (22±13 x 39±29,
p=0.004). The BMC mobilization improved (pre=before, after= >1 month follow-up): the
functional class (from IV-4, III-5 to III-1,II-5, I-3pts), the LVEF (MUGA) (from 21±7.7 to
27±8,6%, p<0.03), the peak oxygen consumption (ml/kg/min) (from 9.6±1.8 to 11.4±1.4,
p=0.01), the quality of life evaluated by the Minnesota Living with Heart Failure Question-
naire (from 70±15 to 33±13, p<0.005). The LV end diastolic diameter, the right ventricular
EF, and the exertional slope VE/Vco2 unchanged. In the 192±114 days follow-up 3 pts
died from: sudden death(1), pulmonary embolism (1),and progressive CHF(1); three pts
were removed from heart transplantation waiting list.Conclusion: The mobilization of
BMC followed by MNC intracoronary infusion is feasible in severe CHF. The mobilization
of BMC by GCS-F is impaired in CHF. The mobilization of BMC can improve selected
severe CHF pts. The mobilization of BMC has potential to become a new hope in CHF.
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814-5 Perfusion and Dilatation of Old Myocardial Infarction 
Improves After Intracoronary Autologous Bone Marrow 
Stem Cell Transplantation
Athanassios Manginas, Dennis V. Cokkinos, Evgenios Goussetis, Ioulia Peristeri, Maria 
Theodosaki, Stelios Graphakos, Evangelos Leontiadis, George Karatasakis, Maria 
Koutelou, Athanassios Theodorakos, Onassis Cardiac Surgery Center, Athens, Greece, 
Aghia Sofia Children's Hospital, Athens, Greece
Background: We sought to evaluate the clinical role of autologous intracoronary adminis-
tration of selected bone marrow derived stem cells (BMSC) in patients with remote non-
viable anterior wall myocardial infarction (AWMI) and patent left anterior descending
artery (LAD).
Methods: Since June 2002 seven male patients (pts) (age 49(+-)9) with history of old
(45(+-)36months) non-viable AWMI were included in the study. Following BM harvesting
(6 pts) or peripheral blood stem cell collection after mobilization with GCSF (1 pt), autolo-
gous AC133+ hematopoetic stem/progenitor cells were isolated using the immunomag-
netic method MACS. Subsequently 15.6(+-)8.5 X 106 BMSC were slowly injected into the
proximal LAD segment. Before and after BMSC transplantation pts underwent dob-
utamine echocardiography (DSE) to determine left ventricular ejection fraction (LVEF),
resting and stress left ventricular endiastolic and endsystolic volumes (rEDV, rESV, sEDV
and sESV respectively) and Tl-201 viability studies (corrected anteroseptal perfusion
defect in counts/pixel, CAPD).
Results: The mean follow-up was 4.6(+-)3.4months. No complications were observed
during clinical follow-up (7(+-)3.6 months).
Conclusions: We observed reduction in the left ventricular dimensions at rest and after
dobutamine, as well as improvement in perfusion of the previously infarcted anterior myo-
cardial segment. Further studies are necessary to elucidate the clinical value of this novel
method of myocardial regeneration.
LVEF (%) rEDV (ml) rESV (ml) sEDV (ml) SESV (ml) Tl-201 CAPD
Baseline 32.2(+-)2.8 230(+-)48 156(+-)35 216(+-)57 139(+-)37 2.65(+-)0.62
Post BMSC 36.8(+-)6.0 220(+-)45 142(+-)36 200(+-)41 122(+-)39 2.33(+-)0.75
P 0.096 0.01 0.057 0.15 0.011 0.039
